Wealth Alliance Advisory Group’s Haemonetics HAE Stock Holding History

Wealth Alliance Advisory Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,000	Closed	-$222K	–	155
2021 Q1	$222K	Hold	2,000	–	–	0.11%	132
2020 Q4	$238K	Buy	+2,000	New	+$215K	0.13%	123
2020 Q1	–	Sell	-2,000	Closed	-$230K	–	127
2019 Q4	$230K	Hold	2,000	–	–	0.13%	118
2019 Q3	$257K	Hold	2,000	–	–	0.16%	97
2019 Q2	$247K	Buy	+2,000	New	+$197K	0.15%	101
2019 Q1	–	Sell	-2,000	Closed	-$200K	–	130
2018 Q4	$200K	Hold	2,000	–	–	0.15%	109
2018 Q3	$229K	Buy	+2,000	New	+$207K	0.12%	118

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

LCOV

London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return

LCP

LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Wealth Alliance Advisory Group's HAE Position: Q2 2021 in Review

Wealth Alliance Advisory Group sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 2,000 shares — an estimated $222K sold.

Wealth Alliance Advisory Group first reported a position in HAE in Q3 2018 and held it in 7 quarters. The position peaked at $257K in Q3 2019. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

Wealth Alliance Advisory Group reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
Wealth Alliance Advisory Group sold 2,000 Haemonetics shares in Q2 2021, an estimated $222K.
Wealth Alliance Advisory Group first reported a position in Haemonetics in Q3 2018 and held it in 7 quarters.
Wealth Alliance Advisory Group's Haemonetics position peaked at $257K in Q3 2019.
258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Wealth Alliance Advisory Group's 13F filing for Q2 2021, filed 13 Jul 2021.